Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
Richard L WuAzza H IdrisNina M BerkowitzMyra HappeMartin R GaudinskiChristian BuettnerLarisa StromSeemal F AwanLaSonji A HolmanFloreliz MendozaIngelise J GordonZonghui HuAndrezza Campos ChagasLawrence T WangLais Da Silva PereiraJoseph R FrancicaNeville K KisaluBarbara J FlynnWei ShiWing-Pui KongSarah O'ConnellSarah H PlummerAllison BeckAdrian McDermottSandeep R NarpalaLeonid SerebryannyyMike CastroRosa SilvaMarjaan ImamIris PittmanSomia P HickmanAndrew J McDougalAshly E LukoskieJittawadee R MurphyJason G GallKevin CarltonPatricia MorganEllie SeoJudy A SteinSandra VazquezShinyi TelscherEdmund V CapparelliEmily E CoatesJohn R MascolaJulie E LedgerwoodLesia K DropulicRobert A Sedernull nullPublished in: The New England journal of medicine (2022)
In this small trial, L9LS administered intravenously or subcutaneously protected recipients against malaria after controlled infection, without evident safety concerns. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 614 ClinicalTrials.gov number, NCT05019729.).